NCT00947167View on ClinicalTrials.gov

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Neuroendocrine TumorsCarcinoid TumorsAdrenal Gland TumorsNeuroblastomaPancreatic Neuroendocrine TumorsMultiple Endocrine Neoplasia
Interventions
DRUG

pertuzumab

840 mg, 420 mg, iv

DRUG

erlotinib

150 mg, PO

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Pamela L. Kunz

OTHER